Evonik Invests in Additional Lipid Production for mRNA-based Vaccines
Evonik has revealed plans for investment in the short-term expansion of its specialty lipids production, which are used with mRNA-based COVID-19 vaccines.
Evonik has revealed plans for investment in the short-term expansion of its specialty lipids production, which are used with mRNA-based COVID-19 vaccines. The announcement was made in a Feb. 11, 2021 press release.
The company’s sites in Hanau and Dossenheim (Germany) will start producing commercial quantities of lipids from the second half of 2021 as a part of a strategic partnership with vaccine manufacturer BioNTech. Through this latest investment, the strategic partnership between Evonik and BioNTech will be strengthened and the supply security of the Pfizer-BioNTech vaccine will be increased.
“The pandemic requires decisive action,” said Christian Kullmann, chairman of Evonik’s executive board, in the press release. “We are therefore doing everything possible to supply our partners with the critical lipids they need. At the same time, we are expanding our production capacity and competencies along the entire value chain.”
“With our partnership with BioNTech, we are systematically expanding our leading position as an integrated development partner in cell and gene therapies,” added Thomas Riermeier, head of Evonik's Health Care business line, in the press release. “Evonik’s portfolio includes pharmaceutical excipients such as lipids, as well as CDMO services for the formulation development, GMP manufacturing, and aseptic filling of complex parenteral drug products.”
Source: Evonik
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
